Who is the assignee on this patent?

Gw Pharma Ltd, Otsuka Pharma Co Ltd

What technology area does this patent fall under?

Primary CPC classification A61K31/337. Mapped technology areas include Human Necessities.

When was this patent published?

Publication date Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.

What related patents are in patentsdb?

We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).

Phytocannabinoids in the treatment of cancer

US9675654B2 · US · B2

Patent metadata
Field	Value
Publication number	US-9675654-B2
Application number	US-201414260876-A
Country	US
Kind code	B2
Filing date	Apr 24, 2014
Priority date	Mar 12, 2010
Publication date	Jun 13, 2017
Grant date	Jun 13, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

Title
What the patent document calls the invention.
Abstract
A short plain-language summary of the technical disclosure.
Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
Key dates
Filing, priority, publication, and grant dates set the timeline.
First independent claim
The legal scope of protection — read this for what is actually claimed.
CPC / IPC classifications
Technology tags used to group this patent with similar filings.
Citations and related patents
Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.

First claim

Opening claim text (preview).

The invention claimed is: 1. A pharmaceutical product consisting essentially of (1) isolated CBD and temazolamide, (2) isolated THC and temazolamide, or (3) a combination of isolated CBD, isolated THC and temazolamide, wherein the pharmaceutical product is packaged for administration separately, simultaneously or sequentially.

Assignees

Classifications

A61P35/04
specific for metastasis · CPC title
A61P35/00
Antineoplastic agents · CPC title
A61P43/00
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
A61P25/00
Drugs for disorders of the nervous system · CPC title
A61P13/08
of the prostate · CPC title

Patent family

Related publications grouped by family.

View patent family 42261478

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9675654B2 cover?: This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.
Who is the assignee on this patent?: Gw Pharma Ltd, Otsuka Pharma Co Ltd
What technology area does this patent fall under?: Primary CPC classification A61K31/337. Mapped technology areas include Human Necessities.
When was this patent published?: Publication date Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?: We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).